

IFw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Group Art Unit: 1645
)	
LINNEN <i>et al.</i>)	Examiner: To Be Assigned
)	
Serial No. 10/825,757)	Atty. Docket No. GP146-04.UT
)	
Filed: April 16, 2004)	Confirmation No. 8545
)	
For: COMPOSITIONS AND METHODS)	
FOR DETERMINING THE)	
PRESENCE OF SARS)	
CORONAVIRUS IN A SAMPLE)	

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b) & (c)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants bring to the Examiner's attention the references listed on the enclosed form PTO/SB/08 (two copies) for consideration in connection with the examination of the above-identified application. A copy of each cited reference is enclosed herewith.

This Information Disclosure Statement is being submitted under 37 C.F.R. § 1.97(b) before the mailing date of a first Office action on the merits. If Applicants are mistaken, and a first Office action on the merits was mailed on or before the certified date of mailing indicated below, then Applicants request that this Information Disclosure Statement be treated as a submission under 37 C.F.R. § 1.97(c) and that the fee due under 37 C.F.R. § 1.17(p) be charged to Deposit Account No. 07-0835 in the name of Gen-Probe Incorporated.

IDS



Serial No.10/825,757
Atty. Docket No.GP146-04.UT

Applicants respectfully request that the Examiner indicate consideration of each cited reference by returning a copy of the enclosed form PTO/SB/08 with the Examiner's initials or other appropriate marks.

Certificate of Mailing

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being deposited on the date indicated below with the U.S. Postal Service as priority mail addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Respectfully submitted,

Date: May 27, 2005

By:

Charles B. Cappellari
Registration No. 40,937
Attorney for Applicants


GEN-PROBE INCORPORATED
Patent Department
10210 Genetic Center Drive
San Diego, California 92121
PH: 858-410-8927
FAX: 858-410-8928



TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number		10/825,757	
		Filing Date		April 16, 2005	
		First Named Inventor		LINNEN <i>et al.</i>	
		Group Art Unit		1645	
		Examiner Name		To Be Assigned	
Total Number of Pages in This Submission		21	Attorney Docket No.		GP146-04.UT
ENCLOSURES (check all that apply)					
<input checked="" type="checkbox"/> Information Disclosure Statement Under 37 CFR § 1.97(b) & (c) <u>2</u> pgs.			<input type="checkbox"/> Other Enclosure(s) (please identify below):		
<input checked="" type="checkbox"/> PTO/SB/08a & b - 9 pgs. in duplicate <u>18</u> pgs.			<input checked="" type="checkbox"/> Return/Prepaid Postcard		
<input checked="" type="checkbox"/> 95 References			Remarks: No fee is believed due with the filing of the Information Disclosure Statement. If Applicants are in error and a fee is due, please debit Deposit Account No. 07-0835, in the name of Gen-Probe Incorporated, the appropriate amount.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm or Individual name		Charles B. Cappellari, Reg. No. 40,937			
Signature					
Date		May 27, 2005			
CERTIFICATE OF MAILING					
I hereby certify that this correspondence is being deposited with the United States Postal Service as priority mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, Washington, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.					
Type or printed name		Charles B. Cappellari, Reg. No. 40,937			
Signature				Date	May 27, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/825,757
Filing Date	April 16, 2004
First Named Inventor	LINNEN <i>et al.</i>
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	GP146-04.UT

(Use as many sheets as necessary)

Sheet 1 of 9

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	6 T
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		CN 1450172 A	10-22-2003	Hangzhou Huada Jene Res Ct		
		DE 20315159 U1	01-22-2004	Artus Ges Fuer Molekularbiolog		X
		WO04/057021 A2	07-08-2004	Université Laval		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645
(Use as many sheets as necessary)				Examiner Name	To Be Assigned
Sheet	2	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		"Artus SARS Test", ABBOTT LABORATORIES, undated, 7 pgs., USA	
		"Meeting to Discuss Development of Diagnostic Test for SARS", Seminar Held in May 29, 2003, 3 pgs., USA	
		"RAT CORONAVIRUSES, Sialodacryoadenitis Virus and Rat Coronavirus: History, Virus Classification, Clinical Disease, Pathology, Diagnosis, Control, Interference with Research and Virus Status of Experimental Rats", CRL, Technical Bulletin, Oct. 1983, 2(2):1-13, USA	
		"CORONAVIRUSES, Severe Acute Respiratory Syndrome (SARS): Read the Facts", Microbiol. & Immuno., BS3035, April 2003, pgs. 1-8, USA	
		"PCR primers for SARS developed by WHO Network Laboratories", World Health Organization, 2003	
		"Cluster of Severe Acute Respiratory Syndrome Cases Among Protected Health-Care Workers---Toronto, Canada, April 2003", CDC, May 16, 2003, MMWR 52(19):433-436, USA	
		"Guidelines for Collection of Specimens from Potential Cases of SARS", CDC, Apr. 23, 2003, pgs. 1-4, USA	
		"SARS Diagnostics: Scientific and Regulatory Challenges", PowerPoint Presentation, U.S. Department of Health and Human Services Food and Drug Administration, Jul. 14, 2003, 10 pgs., USA	
		ALEJSKA et al., "How RNA viruses exchange their genetic material", Acta Biochim. Pol., 2001, 48(2):391-407, Poland	
		ALMAZAN et al., "Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome", Proc. Natl. Acad. Sci., May 9, 2000, 97(10):5516-5521, USA	
		ALONSO et al., "In vitro and in vivo expression of foreign genes by transmissible gastroenteritis coronavirus-derived minigenomes", J. Gen. Virol., 2002, 83:567-579, Great Britain	
		ANAND et al., "Coronavirus Main Proteinase (3CL ^{pro}) Structure: Basis for Design of anti-SARS Drugs", Science (1126/science.1085658), May 13, 2003, 1-10, USA	
		ATMAR et al., "Diagnosis of Noncultivable Gastroenteritis Viruses, the Human Caliciviruses", Clin. Microbiol. Rev., Jan. 2001, 14(1):15-37, ASM, USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645
(Use as many sheets as necessary)				Examiner Name	To Be Assigned
Sheet	3	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		"BARIC et al., "Subgenomic Negative-Strand RNA Function during Mouse Hepatitis Virus Infection", J. Virol., May 2000, 74(9):4039-4046, ASM, USA	
		BOOTH et al., "Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area", JAMA-Express, June 4, 2003, 289(21):1-9, AMA, Canada	
		BUDZILOWICZ et al., "Three Intergenic Regions of Coronavirus Mouse Hepatitis Virus Strain A59 Genome RNA Contain a Common Nucleotide Sequence That is Homologous to the 3' End of the Viral mRNA Leader Sequence", J. Virol., Mar. 1985, 53(3):834-840, ASM, USA	
		CHAN-YEUNG et al., "Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report", BMJ, Apr. 19, 2003, 326:850-852, USA	
		CHANG et al., "The UCUAAAC Promoter Motif Is Not required for High-Frequency Leader Recombination in Bovine Coronavirus Defective Interfering RNA", J. Virol., May 1996, 70(5):2720-2729, ASM, USA	
		CHANG et al., "A cis-Acting Function for the Coronavirus Leader in Defective Interfering RNA Replication", J. Virol., Dec. 1994, 68(12):8223-8231, ASM, USA	
		CURTIS et al., "Heterologous Gene Expression from Transmissible Gastroenteritis Virus Replicon Particles", J. Virol., Feb. 2002, 76(3):1422-1434, ASM, USA	
		de HAAN et al., "Coronaviruses Maintain Viability despite Dramatic Rearrangements of the Strictly Conserved Genome Organization", J. Virol., Dec. 2002, 76(24):12491-12502, ASM, USA	
		DONNELLY et al., "Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong, Lancet, May 7, 2003, pgs. 1-6, Elsevier Science Ltd., Great Britain	
		DRAZEN, "Case Clusters of the Severe Acute Respiratory Syndrome", N. Engl. J. Med., Mar. 23, 2003, pgs. 1-2, Mass. Med. Soc., USA	
		DROSTEN, "Preliminary RT-PCR Protocol for the Coronavirus suspected to be linked with SARS", Bernhard-Nocht-Institute for Tropical Medicine, Mar. 26, 2003, pgs. 1-2, Germany	
		DROSTEN et al., "Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome", N. Engl. J. Med., Apr. 10, 2003, 348(20) 1967-1976, Mass. Med. Soc., USA	
		ENSERINK, "Scientists Chase Fast-Moving and Deadly Global Illness", Science, Mar. 21, 2003, 299:1822, USA	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645
(Use as many sheets as necessary)				Examiner Name	To Be Assigned
Sheet	4	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		EVANS et al., "Utilizing fowlpox virus recombinants to generate defective RNAs of the coronavirus infectious bronchitis virus", J. Gen. Virol., 2000, 81:2855-2865, Great Britain	
		FALSEY et al., "Novel coronavirus and severe acute respiratory syndrome", Lancet, Apr. 8, 2003, 2 pgs., Elsevier Science Ltd., Great Britain	
		FISCHER et al., "Analysis of a Recombinant Mouse Hepatitis Virus Expressing a Foreign Gene Reveals a Novel Aspect of Coronavirus Transcription", J. Virol., Jul. 1997, 71(7):5148-5160, ASM, USA	
		GERBERDING, "Faster...but Fast Enough? Responding to the Epidemic of Severe Acute Respiratory Syndrome", N. Engl. J. Med., 2003, 2 pgs., Mass. Med. Soc., USA	
		GOLD, "SARS genome patent: symptom or disease", Lancet, June 14, 2003, 361:1-2, Elsevier Science Ltd., Great Britain	
		GRADY et al., "Global Collaboration on SARS Bears Fruit", N.Y. Times, May 26, 2003, pgs. 1-5, N.Y. Times Co., USA	
		GRÖNDAHL et al., "Rapid Identification of Nine Microorganisms Causing Acute Respiratory Tract Infections by Single-Tube Multiplex Reverse Transcription-PCR: Feasibility Study", J. Clin. Microbiol., Jan. 1999, 37(1):1-7, ASM, USA	
		HAIJEMA et al., "Switching Species Tropism: an Effective Way to Manipulate the Feline Coronavirus Genome", J. Virol., Apr. 2003, 77(8):4528-4538, ASM, USA	
		HISCOX et al., "Investigation of the Control of Coronavirus Subgenomic mRNA Transcription by Using T7-Generated Negative-Sense RNA Transcripts", J. Virol., Oct. 1995, 69(10):6219-6227, ASM, USA	
		HO, "Guideline on management of severe acute respiratory syndrome (SARS)", Lancet, Apr. 8, 2003, 3 pgs., Elsevier Ltd., USA	
		HOEY, "Updated SARS case definition using laboratory criteria", June 10, 2003, JAMC, 168(12):1566-1567, Can. Med. Assoc., Canada	
		HORIMOTO et al., "Pandemic Threat Posed by Avian Influenza A Viruses", Clin. Microbiol. Rev., Jan. 2001, 14(1):129-149, ASM, USA	
		HSIANG, "Coronaviridae Webpage", Feb. 1, 1999, pgs. 1-7, Stanford Univ., USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645
(Use as many sheets as necessary)				Examiner Name	To Be Assigned
Sheet	5	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HSUE et al., "A Bulged Stem-Loop Structure in the 3' Untranslated Region of the Genome of the Coronavirus Mouse Hepatitis Virus Is Essential for Replication", J. Virol., Oct. 1997, 71(10):7567-7578, ASM, USA	
		HSUE et al., "Characterization of an Essential RNA Secondary Structure in the 3' Untranslated Region of the Murine Coronavirus Genome", J. Virol., Aug. 2000, 74(15):6911-6921, ASM, USA	
		JEONG et al., "Evidence for Coronavirus Discontinuous Transcription", J. Virol., Apr. 1994, 68(4):2615-2623, ASM, USA	
		JOO et al., "Replication of Murine Coronavirus Defective Interfering RNA from Negative-Strand Transcripts", J. Virol., Sept. 1996, 70(9):5769-5776, ASM, USA	
		KEHL et al., "Evaluation of the Hexaplex Assay for Detection of Respiratory Viruses in Children", J. Clin. Microbiol., May 2001, 39(5):1696-1701, ASM, USA	
		KSIAZEK et al., "A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome", N. Engl. J. Med., Apr. 10, 2003, pgs. 1-12, Mass. Med. Soc., USA	
		LAI, "The making of infectious viral RNA: No size limit in sight", Proc. Natl. Acad. Sci., May 9, 2000, 97(10):5025-5027, USA	
		LAI et al., "Characterization of leader RNA sequences on the virion and mRNAs of mouse hepatitis virus, a cytoplasmic RNA virus", Proc. Natl. Acad. Sci., June 1984, 81:3626-3630, USA	
		LAI, "Coronavirus Leader-RNA-Primed Transcription: an Alternative Mechanism to RNA Splicing", BioEssays, undated, 5(6):257-260	
		LAI et al., "Presence of Leader Sequences in the mRNA of Mouse Hepatitis Virus", J. Virol., June 1983, 46(3):1027-1033, ASM, USA	
		LAI et al., "The Molecular Biology of Coronaviruses", Advances in Virus Research, 1997, 48:1-99, Academic Press Inc., USA	
		LAI et al., Further characterization of mRNA's of mouse hepatitis virus: presence of common 5'-end nucleotides", J. Virol., Feb. 1982, 41(2):557-565, ASM, USA (Abstract)	
		LAU et al., "A Real-time PCR for SARS-coronavirus incorporating target gene pre-amplification", Biochem. Biophys. Res. Comm., 2003, 312(4):1290-1296, Elsevier Inc., USA	
		LIAO et al., "Requirement of the 5'-End Genomic Sequence as an Upstream <i>cis</i> -Acting Element for Coronavirus Subgenomic mRNA transcription", J. Virol., Aug. 1994, 68(8):4727-4737, ASM, USA	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645
(Use as many sheets as necessary)				Examiner Name	To Be Assigned
Sheet	6	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		LIN et al., "Identification of the <i>cis</i> -Acting Signal for Minus-Strand RNA Synthesis of a Murine Coronavirus: Implications for the Role of Minus-Strand RNA in RNA Replication and Transcription", J. Virol., Dec. 1994, 68(12):8131-8140, ASM, USA	
		LUMPKIN, Preliminary AdvaMed Recommendations: Ways to Speed Development of Diagnostic Tests for SARS and other Emerging Pathogens", SARS Diagnostics Meeting, 2003, 3 pgs., USA	
		MARRA et al., "The Genome Sequence of the SARS-Associated Coronavirus", Scienceexpress, May 1, 2003, pgs. 1-10, USA	
		MILLER et al., "Synthesis of Subgenomic RNAs by Positive-Strand RNA Viruses", Virology, 2000, 273:1-8, Academic Press Inc., USA	
		NAVAS et al., "Murine Coronavirus Spike Protein Determines the Ability of the Virus To Replicate in the Liver and Cause Hepatitis", J. Virol., Mar. 2001, 75(5):2452-2457, ASM, USA	
		NEWCOMB, "SARS and the New Economics of Biosecurity", Bio-Era, May 2003, pgs. 1-25, USA	
		NIE et al., "Advances in clinical diagnosis and treatment of severe acute respiratory syndrome", World J Gastroenterol, 2003, 9 (6):1139-1143, The WJG Press, China	
		ORTEGO et al., "Generation of a Replication-Competent, Propagation-Deficient Virus Vector Based on the Transmissible Gastroenteritis Coronavirus Genome", J. Virol., Nov. 2002, 76(22):11518-11529, ASM, USA	
		PEIRIS et al., "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study", Lancet, May 24, 2003, 361:1767-1772, Elsevier Science Ltd., Great Britain	
		PEIRIS et al., "Coronavirus as a possible cause of severe acute respiratory syndrome", Lancet, Apr. 8, 2003, pgs. 1-7, Elsevier Science Ltd., Great Britain	
		POLLACK, "Scientists Race to Detect SARS, but First They Must Test the Test", N.Y. Times, June 3, 2003, pgs. 1-4, N.Y. Times Co., USA	
		POON et al., "Rapid Diagnosis of a Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)", Clin. Chem., Apr. 8, 2003, 49(7):1-3, The Assoc. for Clinical Chemistry, USA	
		POUTANEN et al., "Identification of Severe Acute Respiratory Syndrome in Canada", N. Engl. J. Med., Mar. 31, 2003, pgs. 1-11, Mass. Med. Soc., USA	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645
(Use as many sheets as necessary)				Examiner Name	To Be Assigned
Sheet	7	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		RUAN et al., "Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection" Lancet, May 9, 2003, 12 pgs., Elsevier Science Ltd., Great Britain	
		SAMPATHKUMAR et al., "SARS: Epidemiology, Clinical Presentation, Management, and Infection Control Measures", Mayo Clin. Proc., 2003, 78:882-890, Mayo Foundation for Med. Edu. & Rsch., USA	
		SANCHEZ et al., "Targeted Recombination Demonstrates that the Spike Gene of Transmissible Gastroenteritis Coronavirus is a Determinant of Its Enteric Tropism and Virulence", J. Virol., Sept. 1999, 73(9):7607-7618, ASM, USA	
		SENANAYAKE et al., "Translation from the 5' Untranslated Region (UTR) of mRNA 1 Is Repressed, but That from the 5' UTR of mRNA 7 Is Stimulated in Coronavirus-Infected Cells", J. Virol., Oct. 1999, 73(10):8003-8009, ASM, USA	
		SEYBERT et al., "The human coronavirus 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5'-to-3' polarity", RNA, 2000, 6:1056-1068, Cambridge University Press, USA	
		SHEN et al., "Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis", Acta Pharmacol. Sin., June 2003, 24(6):505-511, China	
		SOLA et al., "Engineering the Transmissible Gastroenteritis Virus Genome as an Expression Vector Inducing Lactogenic Immunity", Apr. 2003, J. Virol., 77(7):4357-4369, ASM, USA	
		SPAAN et al., "Transcriptin Strategy of Coronaviruses: Fusion of Non-Contiguous Sequences During mRNA Synthesis", Molecular Biology and Pathogenesis of Coronaviruses, undated, pgs. 173-186, Plenum Press, USA	
		SPAAN et al., "Coronavirus mRNA synthesis involves fusion of non-contiguous sequences", EMBO J., 1983, 2(10):1839-1844, IRL Press Ltd., Great Britain	
		STIRRUPS et al., "Expression of reporter genes from the defective RNA CD-61 of the coronavirus infectious bronchitis virus", J. Gen. Virol., 2000, 81:1687-1698, Great Britain	
		STOHLMAN et al., "Specific Interaction between Coronavirus Leader RNA and Nucleocapsid Protein", Nov. 1988, J. Virol., 62(11):4288-4295, ASM, USA	
		TAGUCHI et al., "A Murine Coronavirus MHV-S Isolate from Persistently Infected Cells Has a Leader and Two Consensus Sequences Between the M and N Genes", Virology, 1994, 198:355-359, Academic Press, Inc., USA	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/825,757
				Filing Date	April 16, 2004
				First Named Inventor	LINNEN <i>et al.</i>
				Art Unit	1645
(Use as many sheets as necessary)				Examiner Name	To Be Assigned
Sheet	8	of	9	Attorney Docket Number	GP146-04.UT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		TAHARA et al., "Coronavirus Translational Regulation: Leader Affects mRNA Efficiency", Virology, 1994, 202:621-630, Academic Press Inc., USA	
		THIEL et al., "Viral Replicase Gene Products Suffice for Coronavirus Discontinuous Transcription", J. Virol., Jul. 2001, 75(14):6676-6681, ASM, USA	
		THIEL et al., "Infectious RNA transcribed <i>in vitro</i> from a cDNA copy of the human coronavirus genome cloned in a vaccinia virus", J. Gen. Virol., 2001, 82:1273-1281, Great Britain	
		TSANG et al., "A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong", N. Engl. J. Med., Mar. 31, 2003, pgs. 1-7, Mass. Med. Soc., USA	
		TYRRELL et al., "Coronaviruses: General Concepts", Graduate School of Biomedical Science: The University of Texas Medical Branch, Medmicro, 2003, Chpt. 60:1-6, USA	
		VABRET et al., "Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction", J. Virol. Meth., Sept. 2001, 97(1-2):59-66, Elsevier Science B.V., Amsterdam	
		VAN MARLE et al., "Arterivirus discontinuous mRNA transcription is guided by base pairing between sense and antisense transcription-regulating sequences", Proc. Natl. Acad. Sci., Oct. 12, 1999, 96(21):12056-12061, USA	
		WANG et al., "Microarray-based detection and genotyping of viral pathogens", Proc. Natl. Acad. Sci., Nov. 26, 2002, 99(24):15687-15692, USA	
		WANG et al., "The Leader RNA of Coronavirus Mouse Hepatitis Virus Contains an Enhancer-Like Element for Subgenomic mRNA Transcription", J. Virol., Nov. 2000, 74(22):10571-10580, ASM, USA	
		ZHANG et al., "Morphology and Morphogenesis of Severe Acute Respiratory Syndrome (SARS)-associated Virus", Acta Biochimica & Biophysica Sinica, 2003, 35(6):587-591, China	
		ZHANG et al., "Identification of a noncanonical signal for transcription of a novel subgenomic mRNA of mouse hepatitis virus: implication for the mechanism of coronavirus RNA transcription", Virology, 2000, 278(1):75-78, Academic Press Inc., USA	
		ZHANG et al., "Coronavirus Leader RNA Regulates and Initiates Subgenomic mRNA Transcription both in <i>trans</i> and in <i>cis</i> ", J. Virol., Aug. 1994, 68(8):4738-4746, ASM, USA	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

